D. Fennelly - Concepedia

Author

D. Fennelly

Also Known As

A. Hanly, D Fennelly, D. FENNELLY, D. Fennelly, D. Fennelly, MD, FRCPI, D. W. Fennelly, D.W. Fennelly, DAVID FENNELLY, David Fennelly, David J. Fennelly

149

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

St. Vincent's University Hospital Memorial Sloan Kettering Cancer Center University College Dublin St. James's Hospital Trinity College Dublin

About

D. Fennelly is an author at St. Vincent's University Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	887
2	Health Sciences	6	6	387
3	Natural Sciences	1	1	46
4	Public Health	1	1	12
5	Cell Biology	1	1	16

D. Fennelly

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer Ronan Ryan, David Gibbons, John Hyland, Histopathology	2005	701
Tumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer Lai Mun Wang, David Kevans, Hugh Mulcahy, The American Journal of Surgical Pathology	2008	276
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. D. Fennelly, Carol Aghajanian, F.L. Shapiro, Journal of Clinical Oncology	1997	249
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Andrew D. Seidman, Daniel Hochhauser, M Gollub, Journal of Clinical Oncology	1996	152
A Simplified Tumor Regression Grade Correlates with Survival in Locally Advanced Rectal Carcinoma Treated with Neoadjuvant Chemoradiotherapy David Beddy, John Hyland, D. C. Winter, Annals of Surgical Oncology Neoadjuvant ChemoradiotherapyRadiation TherapyGastrointestinal OncologyMedicineCancer Recurrence	2008	141
Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy Clifford A. Hudis, Andrew D. Seidman, José Baselga, Journal of Clinical Oncology	1999	116
Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience Sophie Duignan, Donal Maguire, Chamarajanagar S. Ravichand, HPB Surgical OncologyNeoadjuvant ChemoradiotherapyHepatologyMedicineHepatobiliary Tumor	2013	79
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer Robert O’Connor, Michael P. O’Leary, J. Ballot, Cancer Chemotherapy and Pharmacology Advanced CancerOncologyHealth SciencesMedicineImmune Checkpoint Inhibitor	2006	63
Salvage weekly paclitaxel in recurrent ovarian cancer. Nadeem R. Abu‐Rustum, Carol Aghajanian, R.R. Barakat, PubMed	1997	62
Visceral Adiposity is a Risk Factor for Poor Prognosis in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy Chun Seng Lee, David J. Murphy, Colm J. McMahon, Journal of Gastrointestinal Cancer ObesityMetabolic SyndromeBody CompositionCancer RiskGastrointestinal Oncology	2015	58

Page 1